"The best meeting in the field!"
A landmark event, AD/PD brings together neuroscientists, pharmacologists and clinicians to study the industry's hottest topics, similarities and differences and breakthroughs associated with Alzheimer's Disease, Parkinson's Disease and related neurological disorders, and to evaluate advances that may ameliorate many of these diseases.
Geneva, Switzerland, July 27, 2015 – Kenes Group, a leading Professional Conference Organiser (PCO) and Association Management Company (AMC), officially launched its promotional campaign for AD/PD™ 2017, the 13th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, March 29-April 2, 2017, in Vienna, Austria. A valued, long term Kenes client, the AD/PD conferences are organised by association president, Dr. Abraham Fisher and supported by a global committee of medical professionals. A landmark event, AD/PD brings together neuroscientists, pharmacologists and clinicians to study the industry’s hottest topics, similarities and differences and breakthroughs associated with Alzheimer’s Disease, Parkinson’s Disease and related neurological disorders, and to evaluate advances that may ameliorate many of these diseases.
“AD/PD combines all of the neurodegenerative diseases under one roof,” comments Dr. Fisher. “It has become the main platform for the world’s experts to present their latest findings and research in diagnosis, prevention and discovery of new treatment targets for these debilitating disorders.”
The reason for the success is the meetings’ uniqueness, their academic quality combined with the interactive and collegial environment. It is a multidisciplinary mix of participants representing both clinical investigators and basic scientists, as well as both established investigators and young upcoming talents with a concerted attempt to provide an ambience that encourages interaction, exchange of ideas and networking opportunities among all participants. The event is supported by an international Scientific Advisory Board covering a broad range of expertise in AD, PD and related neurological disorders.
“The remarkable success of the series of AD/PD conferences is evident from the progressive increases from one congress to the next, in the number of participants to 3,152 in Nice earlier this year,” commented Dan Rivlin, Kenes CEO. “Delegates hailed from over 80 different countries and the ratio was below the age of 35 – a young and enthusiastic audience welcomed every speaker at every session. Travel grants and various awards to junior faculty, postdoctoral fellows, and graduate students, encouraged attendance by young scientists. At AD/PD 2017 in Vienna, we anticipate attendance of more than 3500 participants,” he added.
But don’t take our word for it… Accolades from AD/PD 2015
“Congratulations once again on a terrific meeting! This really is the best meeting in the field…”
Frank M. LaFerla, USA
“I’ve been pleased to participate in 4 or 5 of the AD/PD meetings. I’ve seen the growth…go from 300 to now 3000 and more participants. It’s a testament to the quality of the scientific advancements in this area.”
John Growdon, USA
“I would like to congratulate you for organising such fantastic meeting which offers wonderful opportunity to establish research network among scholars having similar interests. My friends and I enjoy the meeting very much and benefit from the exciting meeting.”
Jiawei Zhou, China
“Great meeting… A real success.”
John Hardy, UK
“This was a wonderful Conference! The selection of topics was across the board. Lots of new information…I am looking forward to the next Conference.”
Zbigniew K. Wszolek, USA
“The feeling was that we were attending a most important event, which changes the way things will be done from now on. Indeed, a wonderful achievement.”
Hermona Soreq, Israel
About AD/PD™
Neurodegenerative diseases are a serious health challenge facing all societies with ageing demographics. Founded in 1985 by Abraham Fisher and Israel Hanin, AD/PD conferences uniquely combine distinct neurodegenerative diseases in one setting and examine their integration. AD/PD is now the world’s foremost platform devoted to promoting the latest advances in neurodegenerative disease research and new therapies. For more information, visit the website at: www.adpd2017.kenes.com.
For more information, contact:
Magdalina Atanassova
Marketing Communications Manager
Email. matanassova(at)kenes(dot)com
Contact Kenes Group
